KOSPIBiotech & Pharma009420

Hanall Biopharma

₩52,400▼ 2.24%2026-11-18 close
Market Cap
₩2.7T
Turnover
₩13.2B
Volume
250K
Shares out.
52.2M
PER
—
PBR
16.8×
EPS
-₩436
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Clinical readouts and royalties may decide the earnings turn

After an operating loss in 2025, quarterly operating results in 2026 have alternated between profit and loss, and partner clinical data and royalty timing are shaping the direction of earnings.

  1. 1

    Revenue reached KRW 155.2 billion in 2025, growing for three consecutive years from 2023, yet the company posted an operating loss of KRW 916 million and a net loss attributable to controlling shareholders of KRW 5.56 billion.

  2. 2

    Operating profit of KRW 5.6 billion in the second quarter of 2026 was the highest of the last five quarters, but the controlling-shareholder net loss for that quarter was KRW 19.2 billion.

  3. 3

    Third-quarter 2026 operating profit was KRW 1.27 billion, up 265.1% from a year earlier, and controlling-shareholder net profit turned to KRW 3.06 billion. The four-quarter total of controlling-shareholder net losses from Q4 2025 to Q3 2026 is KRW 22.1 billion.

  4. 4

    Earnings combine own-product sales with partner royalties and milestones, so the timing of pipeline data can drive large swings in quarterly results.

  5. 5

    As of early September 2026, consensus pointed to an operating profit for 2026 alongside a net loss attributable to shareholders, a wide gap between operating and net results.

02

Business structure

Hanall Biopharma was founded in 1973 and listed on KOSPI in 1989. It produces and sells more than 160 medicines in categories such as endocrine and cardiovascular, with research, manufacturing and sales of synthetic and biopharmaceutical drugs as its core business.

Overseas clinical and licensing work runs through its U.S. unit HPI. Its flagship pharmaceutical product is a probiotic drug, with 2025 annual sales of KRW 23.8 billion according to company announcements. Nine-month 2026 sales of this product rose 31% year on year to KRW 22.3 billion.

The company reported 2025 pharmaceutical operating sales of KRW 133.8 billion, up 13% year on year, and plans to launch eight new products in 2026.

Its R&D centers on autoimmune therapies, including IMVT-1402 developed with a partner and batoclimab, and the company holds rights to batoclimab outside China, the U.S. and Europe. As of October 2, 2026, Daewoong Pharmaceutical and three related parties held 31.28%, and the National Pension Service held 10.84%.

FcRn-based autoimmune drugs are the key competitive set, and Johnson & Johnson's nipocalimab is cited as a clinical benchmark.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩40.8B₩300M0.9%
2025Q4₩37.5B-₩2B−5.4%
2026Q1₩40B₩800M2.1%
2026Q2₩44.3B₩5.6B12.6%
2026Q3₩39.9B₩1.3B3.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩110B₩1.5B₩300M1.4%0.1%26.9%
2023₩134.9B₩2.2B₩3.5B1.6%1.9%28.7%
2024₩138.9B₩200M-₩1.8B0.2%−1.1%26.5%
2025₩155.2B-₩900M-₩5.6B−0.6%−3.4%39.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 110 billion in 2022 to KRW 134.9 billion in 2023 (up 22.7% year on year), KRW 138.9 billion in 2024 (up 3.0%), and KRW 155.2 billion in 2025 (up 11.7%), growing for three consecutive years from 2023 through 2025. 2025 was the largest revenue year of 2022 through 2025.

Operating profit was KRW 1.51 billion in 2022 and KRW 2.21 billion in 2023 (up 46.9%), then fell to KRW 230 million in 2024 (down 89.6%) before turning into an operating loss of KRW 916 million in 2025. The operating margin moved from 1.4% in 2022 to 1.6% in 2023, 0.2% in 2024 and -0.6% in 2025.

Selling and administrative expenses are cited as a main reason for the 2025 swing to loss, with reports saying they rose 18% to KRW 62.5 billion, driven by international arbitration legal costs with a Chinese partner and a weaker won.

Net profit attributable to controlling shareholders was KRW 251 million in 2022 and KRW 3.51 billion in 2023, then turned to a net loss of KRW 1.8 billion in 2024 and KRW 5.56 billion in 2025, two consecutive years of losses. Net profit including non-controlling interests followed the same direction in 2024 and 2025.

At year-end 2025, total equity was KRW 161.7 billion and total liabilities were KRW 63.5 billion, and the debt ratio rose from 26.5% in 2024 to 39.3% in 2025.

Operating cash flow fell from KRW 25.2 billion in 2022 and KRW 29.6 billion in 2023 to KRW 9.36 billion in 2024, then turned negative at -KRW 2.34 billion in 2025.

Quarterly, operating profit went from KRW 349 million in Q3 2025 to an operating loss of KRW 2.02 billion in Q4 2025, then returned to a profit of KRW 839 million in Q1 2026.

Q2 2026 operating profit of KRW 5.6 billion was attributed in a company-linked earnings comment to deferred revenue recognized after the end of a batoclimab trial, while the controlling-shareholder net loss for that quarter was KRW 19.2 billion.

In Q3 2026, revenue was KRW 39.9 billion, operating profit KRW 1.27 billion and controlling-shareholder net profit KRW 3.06 billion, and the four-quarter total of controlling-shareholder net losses from Q4 2025 to Q3 2026 is KRW 22.1 billion.

05

Industry analysis

The core market is autoimmune therapies that use FcRn inhibition. Eugene Investment & Securities described the FcRn inhibitor market as a fast-growing market in an April 2026 report.

Shinhan Investment Corp. said in a May 29, 2026 report that IMVT-1402 had shown a possible first-in-class success in refractory rheumatoid arthritis through an anti-FcRn mechanism. The same report pointed to a 72.7% ACR20 response at week 16, above 45.5% for Johnson & Johnson's nipocalimab.

This comparison is the brokerage's reading of an interim analysis released by the partner. On September 23, 2026 (local time), the partner announced proof-of-concept Phase 2 results in cutaneous lupus and decided to stop development in that indication.

Daol Investment & Securities said the value loss from that stop was limited, but that the chance of expansion into indications driven less by autoantibodies had fallen.

Batoclimab received orphan drug designation in Japan for thyroid eye disease in February 2025, and the company has named Japan as its fastest commercial path.

Overall, the company combines its own pharmaceutical sales with pipeline licensing and royalty income, so partner clinical timelines and rights negotiations shape its earnings more than the cycle of any downstream market.

06

Outlook

The company plans to launch eight new products in 2026 and said five global clinical readouts from three core assets, batoclimab, IMVT-1402 and tanfanercept, would be released in sequence during 2026.

Of the two batoclimab Phase 3 trials in thyroid eye disease, one was completed at the end of 2025, and the company planned a first topline readout in the first quarter of 2026 and a combined release of the second trial in the first half, according to January 2026 reports.

The company also said that if batoclimab were approved in China within 2026, milestone income could follow. Preparations for a Japanese new-drug application for batoclimab are under way.

Shinhan Investment Corp. said in May 2026 that it was focused on additional IMVT-1402 clinical data expected in 2027, and estimated IMVT-1402 sales excluding refractory rheumatoid arthritis at more than USD 5.1 billion in 2032.

Consensus as of early September 2026 showed an operating profit for 2026 but a net loss attributable to shareholders, and estimates varied widely across brokers.

Shinhan Investment Corp. presented a target price of KRW 130,000 in a May 29, 2026 report, and Hyundai Motor Securities presented KRW 93,000 in a June 1, 2026 report. The next checkpoint is how a 2026 China approval and further IMVT-1402 data feed into reported results.

07

Valuation

PER
—
PBR
16.8×
ROE
-14.2%
EPS
-₩436
BPS
₩3,034
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, earnings-based multiples cannot be calculated. The price-to-book ratio sits in a high range, which means expectations for the pipeline weigh heavily on the share price relative to book value.

Total equity of KRW 161.7 billion at year-end 2025 is entirely attributable to controlling shareholders, and the debt ratio rose from 26.5% in 2024 to 39.3% in 2025. Based on estimates, dividend returns are effectively absent.

Two brokerages set targets around the same period: Shinhan Investment Corp. presented KRW 130,000 in a May 29, 2026 report, and Hyundai Motor Securities presented KRW 93,000 in a June 1, 2026 report. Both cited a revaluation of IMVT-1402 as a basis.

These targets reflect the moment they were issued and may change with later results and clinical data. How the valuation is read depends on whether the weight is placed on pipeline value or on the speed of recovery in core pharmaceutical profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Relative strength of IMVT-1402 clinical data

Interim week-16 data for IMVT-1402 in refractory rheumatoid arthritis, released by the partner, showed a 72.7% ACR20 response. Shinhan Investment Corp. compared this with 45.5% for Johnson & Johnson's nipocalimab and assessed a possible advantage of the anti-FcRn mechanism. If that reading holds, the scope for royalty and milestone income could widen.

Return to quarterly operating profit in 2026

Operating profit turned positive in the first quarter of 2026 at KRW 839 million, then reached KRW 5.6 billion in the second quarter and KRW 1.27 billion in the third. Press reports said ordinary R&D expenses fell 31% year on year in the first quarter.

The company has said the end of international arbitration should ease legal cost burdens. Whether operating profit stays positive quarter after quarter is the key test.

Growth in the pharmaceutical business

According to company announcements, the flagship probiotic product grew from KRW 12.5 billion in 2023 to KRW 23.8 billion in 2025. Nine-month 2026 sales rose 31% year on year to KRW 22.3 billion. The company expects sales of this product to reach around KRW 30 billion in 2026.

09

Bear factors

Gap between recent operating profit and net losses

The controlling-shareholder net loss totals KRW 22.1 billion over the last four quarters, and in Q2 2026 a net loss of KRW 19.2 billion came despite operating profit of KRW 5.6 billion. Consensus in early September 2026 still showed a net loss attributable to shareholders for 2026. Whether operating profit gains start to carry through to net income is an open question.

Pipeline concentration and indication-stop risk

On September 23, 2026 (local time), the partner announced proof-of-concept Phase 2 results in cutaneous lupus and decided to stop development in that indication. Press reports said sentiment weakened after the announcement.

An April 2026 report by Eugene Investment & Securities noted that arbitration over rights reversion linked to development delays was under way.

Cost burden and narrower financial room

Selling and administrative expenses rose 18% to KRW 62.5 billion in 2025, and operating cash flow turned negative at -KRW 2.34 billion. The debt ratio rose from 26.5% in 2024 to 39.3% in 2025.

With total equity of KRW 161.7 billion and total liabilities of KRW 63.5 billion, continued clinical and legal spending could narrow financial room.

10

Risk factors

Clinical and regulatory risk

Clinical readouts for core assets could fall short of expectations or slip. Batoclimab still has thyroid eye disease Phase 3 data and a Japanese filing to prepare, and additional IMVT-1402 data is awaited in 2027. Given a recent indication stop, the value swing from individual results could be large.

Partner and legal risk

The company has said international arbitration with its Chinese partner should end during 2026, but the outcome and timing could change costs and rights arrangements. The timing of Chinese approval determines when milestone income arrives. A brokerage has also pointed to arbitration over rights reversion.

Earnings volatility risk

Own-product sales are growing, but quarterly results swing widely with the timing of partner revenue recognition and selling expense burdens. Third-quarter 2026 operating profit of KRW 1.27 billion fell 77.2% from the prior quarter.

Frequent divergence between operating profit and controlling-shareholder net income also complicates interpretation.

11

What to watch next

  1. By December 31, 2026

    Whether batoclimab receives Chinese approval within the year, as the company hoped, and whether milestone income follows. The end of international arbitration and any decline in legal costs are also due to be visible in this period.

  2. By March 31, 2027

    The filing deadline for the 2026 annual report, the first point at which full-year 2026 results and fourth-quarter operating results are confirmed in a regular filing.

  3. By May 15, 2027

    The filing deadline for the first-quarter 2027 report. It shows whether operating profit stays positive quarter to quarter and whether the gap between operating profit and controlling-shareholder net income narrows.

  4. During 2027 (timing not fixed)

    When the partner discloses additional IMVT-1402 clinical data. Shinhan Investment Corp. said it is focused on 2027 data, and the scale of the rheumatoid arthritis results is a key variable for royalty estimates.

12

Overall view

Hanall Biopharma's revenue rose from KRW 110 billion in 2022 to KRW 155.2 billion in 2025, yet its operating margin slid from 1.4% to -0.6%, and the company swung to an operating loss and a controlling-shareholder net loss in 2025.

Quarterly operating profit in 2026 turned positive in the first quarter and then reached KRW 5.6 billion in the second and KRW 1.27 billion in the third, but controlling-shareholder net losses persisted over the same span, leaving a wide gap between operating and net results.

Own-product growth is visible, especially in the probiotic product, while much of the corporate value depends on the clinical and approval timelines of partner-linked IMVT-1402 and batoclimab. On the strength side are brokerage readings of IMVT-1402 interim data and the return to operating profit.

On the weakness side are four-quarter controlling-shareholder net losses of KRW 22.1 billion, an indication stop, arbitration costs and a higher debt ratio. The balance between these depends on clinical outcomes and the timing of legal cost resolution.

The next checkpoints are the 2026 annual report deadline of March 31, 2027 and the first-quarter 2027 report, where the sustainability of operating profit and the turn in controlling-shareholder results will be tested.

Brokerage target prices reflect the dates they were issued, May and June 2026, and do not capture later changes.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. news.nate.com
  2. comp.wisereport.co.kr
  3. topdaily.kr
  4. markets.hankyung.com
  5. pharmnews.com
  6. hanall.com
  7. v.daum.net
  8. kpanews.co.kr
  9. v.daum.net
  10. ket.kr
  11. hitnews.co.kr
  12. newspim.com
  13. file.alphasquare.co.kr
  14. sedaily.com
  15. m.thinkpool.com
  16. m.thinkpool.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis